# McKesson Corporation

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/McKesson Corporation).

## Overview

McKesson Corp is a healthcare distribution and services company that moves branded, generic, specialty, biosimilar, and OTC medicines through large-scale pharmaceutical logistics networks. It also provides medical-surgical supply distribution, pharmacy technology, specialty health services, and market-access support, with major operations in the United States and Canada.

## Products & services

• U.S. pharmaceutical distribution and logistics
• Medical-surgical supply distribution and biomedical services
• Pharmacy technology and inventory management tools
• Specialty pharmacy, infusion, and patient support services
• Biopharma services and market access consulting
• Community pharmacy programs and purchasing solutions

- **U.S. Pharmaceutical Distribution** (78%) — Distribution and logistics for prescription drugs and related healthcare products across retail, institutional and specialty channels.
- **Medical-Surgical Solutions** (10%) — Medical-supply distribution, logistics, biomedical maintenance and support services for alternate-site providers.
- **International** (9%) — Pharmaceutical wholesale, retail pharmacy, specialty health services and market-access solutions in Canada and Norway.
- **Prescription Technology Solutions** (3%) — Technology-enabled pharmacy workflow, inventory, ordering and automation solutions for pharmacy customers.

- U.S. Pharmaceutical distribution for branded, generic, specialty and OTC drugs
- Medical-Surgical Solutions for alternate-site providers and hospital reference labs
- McKesson Connect, Central Fill, ExpressRx Track and inventory tools
- Specialty pharmacy, infusion clinics and patient support programs in Canada
- Biopharma services, market access consulting and manufacturer logistics
- Independent pharmacy programs such as OneStop Generics and RxOwnership

## Customers

McKesson sells primarily to pharmacies, hospitals, health systems, long-term care providers, oncology and other specialty practices, and other healthcare providers that need reliable drug and supply fulfillment. It also serves pharmaceutical manufacturers and biopharma partners that use McKesson for distribution, patient support, specialty services and market access. In Canada, it reaches retail pharmacies and institutional customers through wholesale distribution and a large pharmacy banner network.

- **Retail national accounts** (primary) — National and regional chains, mail-order pharmacies and mass merchandisers buy high-volume pharmaceutical distribution, central fill and inventory solutions to improve replenishment speed and cost efficiency.
- **Community pharmacies** (primary) — Independent and small-to-medium chain pharmacies buy generics, ordering systems, inventory tools and merchandising programs to improve cash flow and profitability.
- **Institutional healthcare providers** (primary) — Hospitals, health systems, integrated delivery networks and long-term care providers buy pharmaceuticals and medical-surgical supplies to support patient care operations.
- **Specialty and oncology practices** (secondary) — Oncology, specialty and biopharma-related practices buy specialty drug distribution, patient support and logistics services for complex therapies.
- **Pharmaceutical manufacturers and biopharma partners** (secondary) — Manufacturers use McKesson for distribution, logistics, market access and specialty services to reach providers and patients efficiently.

- Retail national accounts that need high-volume drug distribution and replenishment
- Community and independent pharmacies that buy generics, tools and workflow support
- Hospitals, health systems and long-term care providers needing dependable supply
- Oncology and specialty practices that require specialty drug logistics and services
- Pharmaceutical manufacturers and biopharma partners using distribution and access services
- Patients indirectly served through specialty pharmacy, infusion and support programs

## Geography

McKesson is heavily concentrated in the United States, where its pharmaceutical and medical-surgical networks operate through 27 distribution centers and serve the majority of its customer base. Internationally, the company has operations in Canada and a smaller remaining presence in Norway, while it has largely exited other European markets. Geography matters because regulatory regimes, drug pricing, healthcare channel mix and divestiture activity differ materially across these markets.

- **United States** (88%) — Estimated from segment disclosures and the company's U.S.-centric operating footprint.
- **Canada** (11%) — Estimated from International segment disclosures and Canadian wholesale/retail operations.
- **Norway** (1%) — Small remaining European operation within the International segment.

- United States is the core market for pharmaceutical and medical-surgical distribution
- Canada is the main international market and includes wholesale, retail and specialty services
- Norway is the remaining European operating market after broader Europe exits
- U.S. distribution runs through 27 distribution centers and two redistribution centers
- Canada includes a national distribution network and pharmacy banner footprint

## Strategy

McKesson is focused on scaling its core pharmaceutical distribution franchise, expanding specialty and biopharma services, and improving operating efficiency through automation and technology. The company is also reshaping its portfolio through divestitures and separations, including the planned separation of Medical-Surgical Solutions and the exit from non-core international assets. Acquisitions such as PRISM Vision and Core Ventures show a push to broaden specialty healthcare services and deepen customer relationships.

- **Grow specialty and biopharma services** (medium-term) — Specialty therapies are higher-touch and can deepen customer relationships beyond commodity distribution.
- **Improve operating efficiency through automation** (short-term) — Distribution is a low-margin business, so automation and process discipline protect service levels and margins.
- **Portfolio simplification and separation** (medium-term) — Separating non-core assets can improve strategic focus and capital allocation.

- Expand specialty pharmaceutical and biopharma services
- Use automation and technology to improve distribution efficiency
- Separate non-core businesses to sharpen portfolio focus
- Pursue acquisitions that add specialty care capabilities
- Support pharmacy customers with workflow and margin tools
- Optimize network scale across U.S. and Canadian operations

## Risks

McKesson faces litigation, regulatory and reimbursement risk because it operates in highly regulated drug distribution and has been exposed to opioid-related claims and other legal disputes. Its low-margin, high-volume model also depends on uninterrupted logistics, supplier relationships and cybersecurity resilience, while goodwill and acquisition accounting can create future impairment risk if growth assumptions weaken. Changes in drug mix, brand-to-generic conversion, inflation and government actions can quickly affect profitability.

- **Litigation and opioid-related claims** [high] — The company has recorded charges for estimated opioid-related liabilities and continues to face legal disputes.
- **Cybersecurity incidents** [high] — McKesson handles protected health information and critical logistics systems that are attractive targets for cyberattacks.
- **Regulatory and pricing pressure** [high] — Drug distribution and pharmacy services are exposed to healthcare regulation, reimbursement changes and government actions.
- **Goodwill and long-lived asset impairment** [medium] — Acquisitions and portfolio changes require judgment on future cash flows and fair values.

- Opioid and other litigation can create large charges and cash outflows
- Cyberattacks could disrupt healthcare logistics and expose sensitive data
- Regulatory and reimbursement changes can pressure margins and channel economics
- Supply chain interruptions or vendor issues can impair product availability
- Goodwill and acquired assets may be impaired if assumptions deteriorate
- Drug inflation and brand-to-generic mix shifts affect gross profit

## Accounting

McKesson's results are affected by several judgment-heavy accounting areas, especially litigation reserves, restructuring charges and goodwill impairment testing. The company also uses LIFO accounting in its U.S. pharmaceutical business, which can swing gross profit when drug inflation changes, and it records fair value remeasurement gains or losses on divestitures and investments. These items can materially affect comparability between periods even when underlying distribution volumes are stable.

- **Contingent liabilities for opioid-related claims** — Can create large, non-recurring expense and liability swings
- **LIFO inventory accounting** — Can move gross margin up or down with drug price inflation
- **Goodwill impairment testing** — Potential non-cash write-downs in future periods
- **Restructuring and divestiture accounting** — Affects operating profit and period-to-period comparability

- Opioid-related claims require estimates for contingent liabilities
- Restructuring and impairment charges affect operating expense comparability
- LIFO inventory accounting can move gross profit with drug inflation
- Goodwill impairment testing depends on cash flow and market assumptions
- Fair value remeasurement on divestitures can create one-time gains or charges
- Acquisition accounting can raise amortization and integration-related costs

---

*Last updated: 2026-08-11T04:03:56.228997+00:00*